[S02DA03, antipyrine, Antipyrine may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[G03XB02, ulipristal, The metabolism of Ulipristal can be increased when combined with Zaleplon.]
[J01GA01, streptomycin, Zaleplon may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[M03AB01, succinylcholine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Zaleplon.]
[A02BX02, sucralfate, Sucralfate may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[J01CG01, sulbactam, Zaleplon may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[J01EC02, sulfadiazine, Sulfadiazine may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[J01EC01, sulfamethoxazole, Zaleplon may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[M01AB02, sulindac, Sulindac may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N05AL01, sulpiride, The risk or severity of adverse effects can be increased when Sulpiride is combined with Zaleplon.]
[N03AX03, sulthiame, The risk or severity of adverse effects can be increased when Zaleplon is combined with Sulthiame.]
[M01AX04, apazone, Azapropazone may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[L01BB02, mercaptopurine, Zaleplon may increase the excretion rate of Mercaptopurine which could result in a lower serum level and potentially a reduction in efficacy.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be decreased when combined with Zaleplon.]
[N05CD07, temazepam, The risk or severity of adverse effects can be increased when Temazepam is combined with Zaleplon.]
[L01CB02, teniposide, The metabolism of Teniposide can be decreased when combined with Zaleplon.]
[R03CC03, terbutaline, Terbutaline may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[B01AE07, dabigatran etexilate, Zaleplon may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.]
[G03BA03, testosterone, Testosterone may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N07XX06, tetrabenazine, The risk or severity of sedation and somnolence can be increased when Zaleplon is combined with Tetrabenazine.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Zaleplon is combined with Tetracaine.]
[S03AA02, tetracycline, Tetracycline may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[J01DI02, ceftaroline fosamil, Ceftaroline fosamil may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N05AE05, lurasidone, The risk or severity of adverse effects can be increased when Zaleplon is combined with Lurasidone.]
[A04AD10, dronabinol, Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.]
[N04BC07, apomorphine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Zaleplon.]
[L04AX02, thalidomide, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R03DA07, theobromine, Zaleplon may increase the excretion rate of Theobromine which could result in a lower serum level and potentially a reduction in efficacy.]
[R03DA04, theophylline, Zaleplon may increase the excretion rate of Theophylline which could result in a lower serum level and potentially a reduction in efficacy.]
[P02CA02, thiabendazole, Thiabendazole may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[R06AD03, thiethylperazine, The risk or severity of adverse effects can be increased when Thiethylperazine is combined with Zaleplon.]
[N05CA19, thiopental, The risk or severity of adverse effects can be increased when Thiopental is combined with Zaleplon.]
[N05AB08, thioproperazine, The risk or severity of adverse effects can be increased when Zaleplon is combined with Thioproperazine.]
[N05AC02, thioridazine, The risk or severity of adverse effects can be increased when Thioridazine is combined with Zaleplon.]
[N05AF04, thiothixene, The risk or severity of adverse effects can be increased when Zaleplon is combined with Thiothixene.]
[G04BE06, moxisylyte, Zaleplon may decrease the excretion rate of Moxisylyte which could result in a higher serum level.]
[N05AL03, tiapride, The risk or severity of adverse effects can be increased when Zaleplon is combined with Tiapride.]
[B01AC05, ticlopidine, Ticlopidine may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N02AX01, tilidine, The risk or severity of adverse effects can be increased when Zaleplon is combined with Tilidine.]
[S01ED01, timolol, Timolol may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[P01AB02, tinidazole, Tinidazole may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[S01AA12, tobramycin, Zaleplon may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, Tolazamide may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[V04CA01, tolbutamide, Zaleplon may decrease the excretion rate of Tolbutamide which could result in a higher serum level.]
[M02AA21, tolmetin, Tolmetin may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[M03BX04, tolperisone, The risk or severity of adverse effects can be increased when Zaleplon is combined with Tolperisone.]
[N02AX02, tramadol, The risk or severity of CNS depression can be increased when Zaleplon is combined with Tramadol.]
[N06AF04, tranylcypromine, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Zaleplon.]
[N06AX05, trazodone, The risk or severity of adverse effects can be increased when Zaleplon is combined with Trazodone.]
[L01XF01, tretinoin, The metabolism of Zaleplon can be decreased when combined with Tretinoin.]
[S01BA05, triamcinolone, The metabolism of Zaleplon can be increased when combined with Triamcinolone.]
[C03DB02, triamterene, Triamterene may increase the excretion rate of Zaleplon which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD05, triazolam, The risk or severity of adverse effects can be increased when Triazolam is combined with Zaleplon.]
[C03AA06, trichlormethiazide, Trichlormethiazide may increase the excretion rate of Zaleplon which could result in a lower serum level and potentially a reduction in efficacy.]
[A03AB12, mepenzolate, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.]
[A16AX12, trientine, Zaleplon may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.]
[N05AB06, trifluoperazine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Zaleplon.]
[S01AD02, trifluridine, Trifluridine may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N05AD02, trifluperidol, The risk or severity of adverse effects can be increased when Zaleplon is combined with Trifluperidol.]
[N05AA05, triflupromazine, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.]
[N04AA01, trihexyphenidyl, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.]
[R03BA07, mometasone, The metabolism of Zaleplon can be increased when combined with Mometasone.]
[A03AA05, trimebutine, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of adverse effects can be increased when Zaleplon is combined with Alimemazine.]
[N03AC02, trimethadione, The risk or severity of adverse effects can be increased when Trimethadione is combined with Zaleplon.]
[J01EA01, trimethoprim, Trimethoprim may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N06AA06, trimipramine, The risk or severity of adverse effects can be increased when Trimipramine is combined with Zaleplon.]
[R06AX07, triprolidine, The risk or severity of adverse effects can be increased when Triprolidine is combined with Zaleplon.]
[A03BB01, butylscopolamine, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.]
[J01FA08, troleandomycin, The metabolism of Zaleplon can be decreased when combined with Troleandomycin.]
[N06AX24, vilazodone, The risk or severity of adverse effects can be increased when Zaleplon is combined with Vilazodone.]
[N06AX02, tryptophan, The risk or severity of adverse effects can be increased when Tryptophan is combined with Zaleplon.]
[M03AA02, tubocurarine, The risk or severity of adverse effects can be increased when Zaleplon is combined with Tubocurarine.]
[R03DX07, roflumilast, Zaleplon may decrease the excretion rate of Roflumilast which could result in a higher serum level.]
[L01FX04, ipilimumab, Zaleplon may decrease the excretion rate of Ipilimumab which could result in a higher serum level.]
[R02AA14, oxyquinoline, Zaleplon may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[A10BH05, linagliptin, The metabolism of Zaleplon can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Zaleplon can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Zaleplon can be decreased when combined with Telaprevir.]
[S01AA28, vancomycin, Zaleplon may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[N03AX21, ezogabine, The risk or severity of adverse effects can be increased when Zaleplon is combined with Ezogabine.]
[B01AF01, rivaroxaban, Zaleplon may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.]
[B01AC24, ticagrelor, The metabolism of Ticagrelor can be decreased when combined with Zaleplon.]
[C08DA01, verapamil, The metabolism of Zaleplon can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Zaleplon can be decreased when combined with Viloxazine.]
[L01CA02, vincristine, The metabolism of Vincristine can be decreased when combined with Zaleplon.]
[B03BA01, vitamin B12, Cyanocobalamin may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[B01AA03, warfarin, Zaleplon may decrease the excretion rate of Warfarin which could result in a higher serum level.]
[S01AA13, fusidic acid, The metabolism of Zaleplon can be decreased when combined with Fusidic acid.]
[C03BA10, xipamide, Xipamide may increase the excretion rate of Zaleplon which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AF05, zuclopenthixol, The risk or severity of adverse effects can be increased when Zaleplon is combined with Zuclopenthixol.]
[J05AE02, indinavir, The metabolism of Zaleplon can be decreased when combined with Indinavir.]
[N03AX14, levetiracetam, The risk or severity of adverse effects can be increased when Zaleplon is combined with Levetiracetam.]
[M05BA03, pamidronic acid, Pamidronic acid may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[M05BA05, tiludronic acid, Zaleplon may decrease the excretion rate of Tiludronic acid which could result in a higher serum level.]
[B06AC02, icatibant, Zaleplon may decrease the excretion rate of Icatibant which could result in a higher serum level.]
[L01ED01, crizotinib, The metabolism of Crizotinib can be decreased when combined with Zaleplon.]
[A02BC04, rabeprazole, Zaleplon may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[N05AE04, ziprasidone, The risk or severity of adverse effects can be increased when Zaleplon is combined with Ziprasidone.]
[G03AC10, drospirenone, The metabolism of Drospirenone can be increased when combined with Zaleplon.]
[V03AC02, deferiprone, Zaleplon may decrease the excretion rate of Deferiprone which could result in a higher serum level.]
[N02BA01, aspirin, Acetylsalicylic acid may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[L01EJ01, ruxolitinib, Zaleplon may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[G04BD07, tolterodine, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.]
[J01DH04, doripenem, Zaleplon may decrease the excretion rate of Doripenem which could result in a higher serum level.]
[J02AC03, voriconazole, The metabolism of Zaleplon can be decreased when combined with Voriconazole.]
[M03AC04, atracurium, The risk or severity of adverse effects can be increased when Zaleplon is combined with Atracurium.]
[S01FA01, atropine, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[M01CB03, auranofin, Zaleplon may decrease the excretion rate of Auranofin which could result in a higher serum level.]
[L01EK01, axitinib, The metabolism of Axitinib can be decreased when combined with Zaleplon.]
[R07AX02, ivacaftor, The metabolism of Ivacaftor can be decreased when combined with Zaleplon.]
[H02AB11, prednylidene, The metabolism of Zaleplon can be increased when combined with Prednylidene.]
[B03XA04, peginesatide, Zaleplon may decrease the excretion rate of Peginesatide which could result in a higher serum level.]
[L01BC07, azacitidine, Azacitidine may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[L04AX01, azathioprine, Zaleplon may decrease the excretion rate of Azathioprine which could result in a higher serum level.]
[L01BC05, gemcitabine, Gemcitabine may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[J01CA09, azlocillin, The therapeutic efficacy of Zaleplon can be decreased when used in combination with Azlocillin.]
[J01DF01, aztreonam, Aztreonam may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[R02AB04, bacitracin, Bacitracin may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Zaleplon.]
[M03BX01, baclofen, Baclofen may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.]
[A08AA11, lorcaserin, The risk or severity of adverse effects can be increased when Zaleplon is combined with Lorcaserin.]
[G04BD12, mirabegron, Zaleplon may decrease the excretion rate of Mirabegron which could result in a higher serum level.]
[V03AX03, cobicistat, The metabolism of Zaleplon can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Zaleplon can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Zaleplon can be decreased when it is combined with Enzalutamide.]
[N05CA04, barbital, The risk or severity of adverse effects can be increased when Zaleplon is combined with Barbital.]
[D02BA02, octinoxate, Zaleplon may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[J05AE04, nelfinavir, The metabolism of Zaleplon can be decreased when combined with Nelfinavir.]
[S01GA07, brimonidine, Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.]
[N04BD02, rasagiline, The risk or severity of adverse effects can be increased when Zaleplon is combined with Rasagiline.]
[C08CA13, lercanidipine, The metabolism of Zaleplon can be decreased when combined with Lercanidipine.]
[A03FA09, mosapride, The risk or severity of adverse effects can be increased when Zaleplon is combined with Mosapride.]
[N06DA02, donepezil, The risk or severity of adverse effects can be increased when Donepezil is combined with Zaleplon.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.]
[N02CC03, zolmitriptan, The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Zaleplon.]
[R06AC06, thonzylamine, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.]
[G04BD10, darifenacin, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Darifenacin.]
[V09IX04, fluorodeoxyglucose F18, Zaleplon may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[N01AA01, ethyl ether, The risk or severity of adverse effects can be increased when Zaleplon is combined with Diethyl ether.]
[G04BE03, sildenafil, The metabolism of Zaleplon can be decreased when combined with Sildenafil.]
[V08CA11, gadofosveset, Zaleplon may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Zaleplon.]
[B01AF02, apixaban, The metabolism of Apixaban can be decreased when combined with Zaleplon.]
[A16AX08, teduglutide, Zaleplon may decrease the excretion rate of Teduglutide which could result in a higher serum level.]
[A10BH04, alogliptin, Zaleplon may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[A16AX09, glycerol phenylbutyrate, Zaleplon may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.]
[C03AA01, bendroflumethiazide, Bendroflumethiazide may increase the excretion rate of Zaleplon which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX06, pomalidomide, The risk or severity of adverse effects can be increased when Zaleplon is combined with Pomalidomide.]
[N02BA10, benorilate, Benorilate may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N05AD07, benperidol, The risk or severity of adverse effects can be increased when Zaleplon is combined with Benperidol.]
[A10BK02, canagliflozin, Canagliflozin may increase the excretion rate of Zaleplon which could result in a lower serum level and potentially a reduction in efficacy.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Zaleplon is combined with Benzocaine.]
[L03AA12, ancestim, Zaleplon may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, Celecoxib may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N02CC02, naratriptan, The risk or severity of adverse effects can be increased when Naratriptan is combined with Zaleplon.]
[N04AC01, benztropine, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Benzatropine.]
[L01EC02, dabrafenib, The serum concentration of Zaleplon can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, Benzydamine may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[L01EE01, trametinib, Zaleplon may decrease the excretion rate of Trametinib which could result in a higher serum level.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Zaleplon is combined with Benzyl alcohol.]
[V09AX05, florbetapir F-18, Zaleplon may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[N06AX28, levomilnacipran, The risk or severity of adverse effects can be increased when Zaleplon is combined with Levomilnacipran.]
[A10BJ03, lixisenatide, Zaleplon may decrease the excretion rate of Lixisenatide which could result in a higher serum level.]
[C02KX04, macitentan, Zaleplon may decrease the excretion rate of Macitentan which could result in a higher serum level.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Zaleplon.]
[N06AX26, vortioxetine, The risk or severity of adverse effects can be increased when Zaleplon is combined with Vortioxetine.]
[G03AC08, etonogestrel, The metabolism of Etonogestrel can be increased when combined with Zaleplon.]
[N03AF04, eslicarbazepine, The risk or severity of adverse effects can be increased when Zaleplon is combined with Eslicarbazepine.]
[J05AP05, simeprevir, The metabolism of Zaleplon can be decreased when combined with Simeprevir.]
[J05AP08, sofosbuvir, Zaleplon may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.]
[N03AG04, vigabatrin, The risk or severity of adverse effects can be increased when Zaleplon is combined with Vigabatrin.]
[A10BK01, dapagliflozin, Dapagliflozin may increase the excretion rate of Zaleplon which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA27, droxidopa, Zaleplon may decrease the excretion rate of Droxidopa which could result in a higher serum level.]
[N05CH03, tasimelteon, The risk or severity of adverse effects can be increased when Zaleplon is combined with Tasimelteon.]
[A16AA07, metreleptin, The metabolism of Zaleplon can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Zaleplon can be increased when combined with Apremilast.]
[L02BG02, formestane, Zaleplon may decrease the excretion rate of Formestane which could result in a higher serum level.]
[S03BA03, betamethasone, The metabolism of Zaleplon can be increased when combined with Betamethasone.]
[V03AB34, fomepizole, Zaleplon may decrease the excretion rate of Fomepizole which could result in a higher serum level.]
[L04AC11, siltuximab, The metabolism of Zaleplon can be increased when combined with Siltuximab.]
[A03BA03, hyoscyamine, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.]
[N01AX05, alfaxalone, The risk or severity of adverse effects can be increased when Zaleplon is combined with Alfaxalone.]
[V08AA01, diatrizoic acid, Diatrizoate may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[D11AA01, glycopyrronium, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.]
[V08AA04, iothalamic acid, Diatrizoate may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N05CM19, suvorexant, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[S01AA15, dihydrostreptomycin, Dihydrostreptomycin may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N05AA04, acepromazine, The risk or severity of adverse effects can be increased when Zaleplon is combined with Acepromazine.]
[N04AA02, biperiden, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Biperiden.]
[S03AA06, gentamicin, Zaleplon may decrease the excretion rate of Gentamicin which could result in a higher serum level.]
[L01XK01, olaparib, The metabolism of Olaparib can be decreased when combined with Zaleplon.]
[B01AF03, edoxaban, Zaleplon may decrease the excretion rate of Edoxaban which could result in a higher serum level.]
[N06AX11, mirtazapine, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Zaleplon can be increased when combined with Secukinumab.]
[J05AP07, daclatasvir, The metabolism of Daclatasvir can be decreased when combined with Zaleplon.]
[N02BE01, acetaminophen, Acetaminophen may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[L01DC01, bleomycin, Bleomycin may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[A03AA09, difemerine, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Difemerine.]
[J05AF08, adefovir dipivoxil, Adefovir dipivoxil may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[J05AP06, asunaprevir, The metabolism of Asunaprevir can be decreased when combined with Zaleplon.]
[N05AX16, brexpiprazole, The risk or severity of adverse effects can be increased when Zaleplon is combined with Brexpiprazole.]
[G02CX02, flibanserin, The risk or severity of adverse effects can be increased when Zaleplon is combined with Flibanserin.]
[N05AX15, cariprazine, The risk or severity of adverse effects can be increased when Zaleplon is combined with Cariprazine.]
[M02AA25, aceclofenac, Aceclofenac may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[M01AB11, acemetacin, Acemetacin may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[S01EC01, acetazolamide, The risk or severity of adverse effects can be increased when Acetazolamide is combined with Zaleplon.]
[N05AB07, acetophenazine, The risk or severity of adverse effects can be increased when Zaleplon is combined with Acetophenazine.]
[V03AB37, idarucizumab, Zaleplon may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[J02AC05, isavuconazole, The metabolism of Zaleplon can be decreased when combined with Isavuconazole.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Zaleplon.]
[L01XG03, ixazomib, Zaleplon may decrease the excretion rate of Ixazomib which could result in a higher serum level.]
[M04AB05, lesinurad, Zaleplon may decrease the excretion rate of Lesinurad which could result in a higher serum level.]
[J05AP10, elbasvir, The metabolism of Elbasvir can be decreased when combined with Zaleplon.]
[N05CA05, aprobarbital, The risk or severity of adverse effects can be increased when Zaleplon is combined with Aprobarbital.]
[M01AE16, alminoprofen, Alminoprofen may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N03AX23, brivaracetam, The risk or severity of adverse effects can be increased when Zaleplon is combined with Brivaracetam.]
[L01XX52, venetoclax, The metabolism of Zaleplon can be decreased when combined with Venetoclax.]
[N05BA08, bromazepam, The risk or severity of adverse effects can be increased when Zaleplon is combined with Bromazepam.]
[N04BC01, bromocriptine, The risk or severity of adverse effects can be increased when Zaleplon is combined with Bromocriptine.]
[A02AD05, aluminum magnesium silicate, Zaleplon may decrease the excretion rate of Almasilate which could result in a higher serum level.]
[A03AX08, alverine, The risk or severity of adverse effects can be increased when Zaleplon is combined with Alverine.]
[R06AB01, brompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Zaleplon.]
[N06AA19, amineptin, The risk or severity of adverse effects can be increased when Zaleplon is combined with Amineptine.]
[N06BX11, aniracetam, The risk or severity of adverse effects can be increased when Zaleplon is combined with Aniracetam.]
[C03CA02, bumetanide, Bumetanide may increase the excretion rate of Zaleplon which could result in a lower serum level and potentially a reduction in efficacy.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Zaleplon is combined with Bupivacaine.]
[N07BC01, buprenorphine, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05BE01, buspirone, The risk or severity of adverse effects can be increased when Buspirone is combined with Zaleplon.]
[L01XX27, arsenic trioxide, Zaleplon may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[P01BE02, artemether, The metabolism of Artemether can be decreased when combined with Zaleplon.]
[M02AA03, clofezone, Zaleplon may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[N02AF01, butorphanol, The risk or severity of adverse effects can be increased when Butorphanol is combined with Zaleplon.]
[R06AX09, azatadine, The therapeutic efficacy of Zaleplon can be decreased when used in combination with Azatadine.]
[S01GX07, azelastine, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[L01XK03, rucaparib, The metabolism of Zaleplon can be decreased when combined with Rucaparib.]
[L01EF02, ribociclib, The metabolism of Zaleplon can be decreased when combined with Ribociclib.]
[A07EC04, balsalazide, Balsalazide may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[R03DA08, bamifylline, Zaleplon may increase the excretion rate of Bamifylline which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AH05, naldemedine, Zaleplon may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, The risk or severity of sedation and somnolence can be increased when Zaleplon is combined with Deutetrabenazine.]
[N02BF02, pregabalin, The therapeutic efficacy of Zaleplon can be increased when used in combination with Pregabalin.]
[N03AX30, beclamide, The risk or severity of adverse effects can be increased when Zaleplon is combined with Beclamide.]
[N06BC01, caffeine, Zaleplon may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Zaleplon is combined with Oxybuprocaine.]
[P01CA02, benznidazole, Zaleplon may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[J01XX08, linezolid, The therapeutic efficacy of Zaleplon can be decreased when used in combination with Linezolid.]
[J05AF06, abacavir, Zaleplon may decrease the excretion rate of Abacavir which could result in a higher serum level.]
[J05AE09, tipranavir, The metabolism of Zaleplon can be decreased when combined with Tipranavir.]
[N07XX13, valbenazine, Zaleplon may decrease the excretion rate of Valbenazine which could result in a higher serum level.]
[L04AB02, infliximab, The metabolism of Zaleplon can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Zaleplon can be decreased when combined with Midostaurin.]
[N04BD03, safinamide, The risk or severity of adverse effects can be increased when Zaleplon is combined with Safinamide.]
[J01MA23, delafloxacin, Zaleplon may decrease the excretion rate of Delafloxacin which could result in a higher serum level.]
[L01BC06, capecitabine, Zaleplon may decrease the excretion rate of Capecitabine which could result in a higher serum level.]
[L01EM02, copanlisib, The metabolism of Copanlisib can be decreased when combined with Zaleplon.]
[C07AB07, bisoprolol, Bisoprolol may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[J05AG03, efavirenz, The metabolism of Zaleplon can be decreased when combined with Efavirenz.]
[J01DC10, cefprozil, Cefprozil may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N04AA11, bornaprine, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Bornaprine.]
[N05AD06, bromperidol, The risk or severity of adverse effects can be increased when Zaleplon is combined with Bromperidol.]
[N05CD09, brotizolam, The risk or severity of adverse effects can be increased when Zaleplon is combined with Brotizolam.]
[C03DA03, canrenone, Canrenone may increase the excretion rate of Zaleplon which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA02, budesonide, The metabolism of Zaleplon can be increased when combined with Budesonide.]
[M01AB07, bumadizone, Bumadizone may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[L01EL02, acalabrutinib, The metabolism of Zaleplon can be decreased when combined with Acalabrutinib.]
[N05CA03, butobarbital, The risk or severity of adverse effects can be increased when Zaleplon is combined with Butobarbital.]
[J05AX18, letermovir, The metabolism of Zaleplon can be decreased when combined with Letermovir.]
[N06AA15, butriptyline, The risk or severity of adverse effects can be increased when Zaleplon is combined with Butriptyline.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Zaleplon is combined with Capsaicin.]
[A10BK04, ertugliflozin, Ertugliflozin may increase the excretion rate of Zaleplon which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CA08, butylvinal, The risk or severity of adverse effects can be increased when Zaleplon is combined with Vinylbital.]
[R06AX18, acrivastine, Zaleplon may decrease the excretion rate of Acrivastine which could result in a higher serum level.]
[L02BB05, apalutamide, The metabolism of Zaleplon can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, Carbamazepine may increase the Change in thyroid function activities of Zaleplon.]
[A03AA03, camylofine, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Camylofin.]
[R06AA08, carbinoxamine, The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Zaleplon.]
[N03AX24, cannabidiol, The risk or severity of adverse effects can be increased when Cannabidiol is combined with Zaleplon.]
[L04AA37, baricitinib, Zaleplon may decrease the excretion rate of Baricitinib which could result in a higher serum level.]
[J01DE01, cefepime, Cefepime may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[J01DD10, cefetamet, Cefetamet may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[J01DD09, cefodizime, Cefodizime may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[J01DC11, ceforanide, Ceforanide may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[J01DD13, cefpodoxime, Cefpodoxime may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[J01DD14, ceftibuten, Ceftibuten may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[J01GB14, plazomicin, Zaleplon may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[L01XX62, ivosidenib, The metabolism of Zaleplon can be increased when combined with Ivosidenib.]
[A16AX14, migalastat, Zaleplon may decrease the excretion rate of Migalastat which could result in a higher serum level.]
[N03AX17, stiripentol, The metabolism of Zaleplon can be decreased when combined with Stiripentol.]
[J05AG06, doravirine, The metabolism of Doravirine can be decreased when combined with Zaleplon.]
[S01GX12, cetirizine, The risk or severity of adverse effects can be increased when Cetirizine is combined with Zaleplon.]
[N05CM04, carbromal, The risk or severity of adverse effects can be increased when Zaleplon is combined with Carbromal.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Zaleplon is combined with Chloroprocaine.]
[D08AE05, chloroxylenol, Zaleplon may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[R06AA06, chlorphenoxamine, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.]
[M01AC05, lornoxicam, Lornoxicam may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[R03DA02, oxtriphylline, Zaleplon may increase the excretion rate of Oxtriphylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N07XX15, inotersen, Inotersen may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Zaleplon.]
[R03BB08, revefenacin, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Revefenacin.]
[L01ED05, lorlatinib, The metabolism of Lorlatinib can be decreased when combined with Zaleplon.]
[L04AA39, emapalumab, The metabolism of Zaleplon can be increased when combined with Emapalumab.]
[L01AD01, carmustine, Carmustine may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[A06AX05, prucalopride, Zaleplon may decrease the excretion rate of Prucalopride which could result in a higher serum level.]
[B01AC23, cilostazol, Zaleplon may decrease the excretion rate of Cilostazol which could result in a higher serum level.]
[A03FA08, cinitapride, The risk or severity of adverse effects can be increased when Zaleplon is combined with Cinitapride.]
[N06AX27, esketamine, The risk or severity of adverse effects can be increased when Zaleplon is combined with Esketamine.]
[J01FA09, clarithromycin, The metabolism of Zaleplon can be decreased when combined with Clarithromycin.]
[N06BA14, solriamfetol, The risk or severity of adverse effects can be increased when Zaleplon is combined with Solriamfetol.]
[N06AX29, brexanolone, The risk or severity of adverse effects can be increased when Zaleplon is combined with Brexanolone.]
[N05BA09, clobazam, The risk or severity of adverse effects can be increased when Clobazam is combined with Zaleplon.]
[H02AB14, cloprednol, The metabolism of Zaleplon can be increased when combined with Cloprednol.]
[N05BA22, cloxazolam, The risk or severity of adverse effects can be increased when Zaleplon is combined with Cloxazolam.]
[L04AB01, etanercept, The metabolism of Zaleplon can be increased when combined with Etanercept.]
[H02AB17, cortivazol, The metabolism of Zaleplon can be increased when combined with Cortivazol.]
[J01DC04, cefaclor, Cefaclor may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[J01DB05, cefadroxil, Cefadroxil may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[J01DC03, cefamandole, Cefamandole may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[J01DB07, cefatrizine, Cefatrizine may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[J01DB04, cefazolin, Cefazolin may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[J01DC09, cefmetazole, Cefmetazole may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[J01DC06, cefonicid, Cefonicid may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[J01DD12, cefoperazone, Cefoperazone may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[J01DD01, cefotaxime, The therapeutic efficacy of Zaleplon can be decreased when used in combination with Cefotaxime.]
[J01DC05, cefotetan, Cefotetan may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N05AA06, cyamemazine, The risk or severity of adverse effects can be increased when Zaleplon is combined with Cyamemazine.]
[J01DC07, cefotiam, Cefotiam may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[J01DC01, cefoxitin, Cefoxitin may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[J01DD03, cefsulodin, Cefsulodin may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[J01DD02, ceftazidime, Ceftazidime may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[C03BX03, cicletanine, Cicletanine may increase the excretion rate of Zaleplon which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD07, ceftizoxime, Ceftizoxime may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[J01DD04, ceftriaxone, Ceftriaxone may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[S01AA27, cefuroxime, Cefuroxime may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[M03BX08, cyclobenzaprine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Zaleplon.]
[N07XX11, pitolisant, The serum concentration of Zaleplon can be decreased when it is combined with Pitolisant.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Zaleplon.]
[C03AA09, cyclothiazide, Cyclothiazide may increase the excretion rate of Zaleplon which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BE04, yohimbine, The risk or severity of adverse effects can be increased when Zaleplon is combined with Yohimbine.]
[J01XX09, daptomycin, Daptomycin may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[J01DB01, cephalexin, Cephalexin may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[J01DB02, cephaloridine, Cefaloridine may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[J01DB03, cephalothin, The therapeutic efficacy of Zaleplon can be decreased when used in combination with Cefalotin.]
[J01DB08, cephapirin, Cefapirin may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[J01DB09, cephradine, Cefradine may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[G03DB05, demegestone, The metabolism of Demegestone can be increased when combined with Zaleplon.]
[L01FD03, ado-trastuzumab emtansine, The metabolism of Trastuzumab emtansine can be decreased when combined with Zaleplon.]
[N02CC08, lasmiditan, The risk or severity of adverse effects can be increased when Lasmiditan is combined with Zaleplon.]
[G03AC09, desogestrel, The metabolism of Desogestrel can be increased when combined with Zaleplon.]
[N03AX25, cenobamate, The serum concentration of Zaleplon can be decreased when it is combined with Cenobamate.]
[A16AX16, givosiran, Givosiran may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[M09AX08, golodirsen, Zaleplon may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[R06AB06, dexbrompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Zaleplon.]
[R06AB02, dexchlorpheniramine, The therapeutic efficacy of Zaleplon can be decreased when used in combination with Dexchlorpheniramine.]
[S01XA12, dexpanthenol, Zaleplon may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[N02AX03, dezocine, The risk or severity of adverse effects can be increased when Zaleplon is combined with Dezocine.]
[N05CM21, lemborexant, The risk or severity of adverse effects can be increased when Zaleplon is combined with Lemborexant.]
[N05AD10, lumateperone, The risk or severity of adverse effects can be increased when Zaleplon is combined with Lumateperone.]
[H02CA02, osilodrostat, The metabolism of Zaleplon can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Zaleplon can be decreased when combined with Amprenavir.]
[N02CC07, frovatriptan, The risk or severity of adverse effects can be increased when Zaleplon is combined with Frovatriptan.]
[G04CB02, dutasteride, The metabolism of Dutasteride can be decreased when combined with Zaleplon.]
[N05CC04, dichloralphenazone, The risk or severity of adverse effects can be increased when Zaleplon is combined with Dichloralphenazone.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Zaleplon.]
[R02AA03, dichlorobenzyl alcohol, Zaleplon may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, The metabolism of Dienogest can be increased when combined with Zaleplon.]
[A07DA04, difenoxin, The risk or severity of adverse effects can be increased when Zaleplon is combined with Difenoxin.]
[N02AA08, dihydrocodeine, The risk or severity of adverse effects can be increased when Zaleplon is combined with Dihydrocodeine.]
[N02CC06, eletriptan, The risk or severity of adverse effects can be increased when Eletriptan is combined with Zaleplon.]
[M01AH02, rofecoxib, Rofecoxib may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[C08CA16, clevidipine, Zaleplon may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C01BD07, dronedarone, The metabolism of Dronedarone can be decreased when combined with Zaleplon.]
[N03AG02, dipropylacetamide, The risk or severity of adverse effects can be increased when Zaleplon is combined with Valpromide.]
[L01AA02, chlorambucil, The therapeutic efficacy of Zaleplon can be decreased when used in combination with Chlorambucil.]
[S03AA08, chloramphenicol, The metabolism of Zaleplon can be decreased when combined with Chloramphenicol.]
[N05BA02, chlordiazepoxide, The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Zaleplon.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Zaleplon.]
[A03AA08, dihexyverine, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.]
[D07XB03, fluprednidene, The metabolism of Zaleplon can be increased when combined with Fluprednidene.]
[G04BD09, trospium, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Trospium.]
[M01AC04, droxicam, Droxicam may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[V08CA05, mangafodipir, Zaleplon may decrease the excretion rate of Mangafodipir which could result in a higher serum level.]
[M02AA27, dexketoprofen, Dexketoprofen may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N05CM02, chlormethiazole, The risk or severity of adverse effects can be increased when Zaleplon is combined with Clomethiazole.]
[M03BB02, chlormezanone, The risk or severity of adverse effects can be increased when Zaleplon is combined with Chlormezanone.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Zaleplon is combined with Dyclonine.]
[C08CA17, levamlodipine, The metabolism of Levamlodipine can be decreased when combined with Zaleplon.]
[N05CD14, remimazolam, The risk or severity of adverse effects can be increased when Zaleplon is combined with Remimazolam.]
[L04AC19, satralizumab, The serum concentration of Zaleplon can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Zaleplon is combined with Oliceridine.]
[P01BA01, chloroquine, The therapeutic efficacy of Zaleplon can be decreased when used in combination with Chloroquine.]
[L01EX23, pralsetinib, The metabolism of Zaleplon can be decreased when combined with Pralsetinib.]
[C03AA04, chlorothiazide, Chlorothiazide may increase the excretion rate of Zaleplon which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AB04, chlorpheniramine, The risk or severity of adverse effects can be increased when Zaleplon is combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.]
[A10BB02, chlorpropamide, Chlorpropamide may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N05AF03, chlorprothixene, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.]
[C03BA04, chlorthalidone, Chlorthalidone may increase the excretion rate of Zaleplon which could result in a lower serum level and potentially a reduction in efficacy.]
[M03BB03, chlorzoxazone, The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Zaleplon.]
[N05BX03, etifoxine, The risk or severity of adverse effects can be increased when Zaleplon is combined with Etifoxine.]
[N02BA07, ethenzamide, Ethenzamide may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N02BA03, choline salicylate, Zaleplon may decrease the excretion rate of Choline salicylate which could result in a higher serum level.]
[N06BX18, vinpocetine, The risk or severity of adverse effects can be increased when Zaleplon is combined with Vinpocetine.]
[N05BA18, ethyl loflazepate, The risk or severity of adverse effects can be increased when Zaleplon is combined with Ethyl loflazepate.]
[G03DC06, ethynodiol, The metabolism of Etynodiol can be increased when combined with Zaleplon.]
[M01AB08, etodolac, Etodolac may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[M02AA06, etofenamate, Etofenamate may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[B06AC06, berotralstat, The metabolism of Zaleplon can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Zaleplon can be decreased when combined with Lonafarnib.]
[L02BX04, relugolix, The metabolism of Relugolix can be decreased when combined with Zaleplon.]
[M01AX25, chondroitin sulfates, Zaleplon may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[P03AX07, abametapir, The serum concentration of Zaleplon can be increased when it is combined with Abametapir.]
[M03BA05, febarbamate, The risk or severity of adverse effects can be increased when Zaleplon is combined with Febarbamate.]
[N03AX10, felbamate, The risk or severity of adverse effects can be increased when Felbamate is combined with Zaleplon.]
[M01AE05, fenbufen, Fenbufen may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N06BA10, fenethylline, Zaleplon may increase the excretion rate of Fenethylline which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA19, fenoldopam, Fenoldopam may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[G04CB01, finasteride, The metabolism of Finasteride can be decreased when combined with Zaleplon.]
[J01DD15, cefdinir, Cefdinir may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[S02BA08, fluocinolone acetonide, Fluocinolone acetonide may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N02BG07, flupirtine, Zaleplon may decrease the excretion rate of Flupirtine which could result in a higher serum level.]
[L04AA50, ponesimod, The metabolism of Ponesimod can be decreased when combined with Zaleplon.]
[N01AB05, trichloroethylene, The risk or severity of adverse effects can be increased when Zaleplon is combined with Trichloroethylene.]
[A02BA01, cimetidine, The metabolism of Zaleplon can be decreased when combined with Cimetidine.]
[N02BF01, gabapentin, The risk or severity of adverse effects can be increased when Zaleplon is combined with Gabapentin.]
[V08CA04, gadoteridol, Gadoteridol may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[L01XX73, sotorasib, The serum concentration of Zaleplon can be decreased when it is combined with Sotorasib.]
[S03AA07, ciprofloxacin, The metabolism of Zaleplon can be decreased when combined with Ciprofloxacin.]
[L01XA01, cisplatin, Zaleplon may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N06AB04, citalopram, The risk or severity of adverse effects can be increased when Zaleplon is combined with Citalopram.]
[C03DA05, finerenone, Finerenone may increase the excretion rate of Zaleplon which could result in a lower serum level and potentially a reduction in efficacy.]
[P01CA03, fexinidazole, The metabolism of Fexinidazole can be decreased when combined with Zaleplon.]
[L01EB10, mobocertinib, The metabolism of Mobocertinib can be decreased when combined with Zaleplon.]
[V09AB03, ioflupane I-123, Zaleplon may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.]
[V09AA01, technetium Tc 99m exametazime, Zaleplon may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[V09AX06, florbetaben f-18, Zaleplon may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[R06AA04, clemastine, The risk or severity of adverse effects can be increased when Clemastine is combined with Zaleplon.]
[M01AG01, mefenamic acid, Mefenamic acid may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[J01FF01, clindamycin, The metabolism of Clindamycin can be decreased when combined with Zaleplon.]
[N06AX25, St. John's wort extract, The metabolism of Zaleplon can be increased when combined with St. John's Wort.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Zaleplon.]
[J04BA01, clofazimine, The metabolism of Zaleplon can be decreased when combined with Clofazimine.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Zaleplon is combined with Levobupivacaine.]
[N06AA04, clomipramine, The risk or severity of adverse effects can be increased when Zaleplon is combined with Clomipramine.]
[N03AE01, clonazepam, The risk or severity of adverse effects can be increased when Zaleplon is combined with Clonazepam.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Zaleplon.]
[C01EB24, mavacamten, The serum concentration of Zaleplon can be decreased when it is combined with Mavacamten.]
[J05AH02, oseltamivir, Oseltamivir may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[C03BA03, clopamide, Clopamide may increase the excretion rate of Zaleplon which could result in a lower serum level and potentially a reduction in efficacy.]
[A02BC08, vonoprazan, The metabolism of Vonoprazan can be decreased when combined with Zaleplon.]
[N05AH06, clothiapine, The risk or severity of adverse effects can be increased when Zaleplon is combined with Clothiapine.]
[N05BA21, clotiazepam, The risk or severity of adverse effects can be increased when Zaleplon is combined with Clotiazepam.]
[A04AA01, ondansetron, The risk or severity of adverse effects can be increased when Ondansetron is combined with Zaleplon.]
[A04AA02, granisetron, The risk or severity of adverse effects can be increased when Granisetron is combined with Zaleplon.]
[N05AH02, clozapine, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Clozapine.]
[J01GB12, arbekacin, Zaleplon may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[N05BA13, halazepam, The risk or severity of adverse effects can be increased when Halazepam is combined with Zaleplon.]
[H01AC08, somatrogon, The metabolism of Zaleplon can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Zaleplon is combined with Cocaine.]
[C02KB01, metyrosine, Zaleplon may increase the sedative activities of Metyrosine.]
[L04AC21, bimekizumab, The metabolism of Zaleplon can be increased when combined with Bimekizumab.]
[M01AX13, proquazone, Proquazone may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Codeine is combined with Zaleplon.]
[M03AC05, hexafluorenium, The risk or severity of adverse effects can be increased when Hexafluronium is combined with Zaleplon.]
[M04AC01, colchicine, Zaleplon may decrease the excretion rate of Colchicine which could result in a higher serum level.]
[A03AB10, hexocyclium, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.]
[A03BB06, homatropine methylbromide, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.]
[J01XB01, colistin, Zaleplon may decrease the excretion rate of Colistin which could result in a higher serum level.]
[J01DE02, cefpirome, Cefpirome may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N01AB07, desflurane, The risk or severity of adverse effects can be increased when Zaleplon is combined with Desflurane.]
[A04AA03, tropisetron, The risk or severity of adverse effects can be increased when Zaleplon is combined with Tropisetron.]
[C04AX28, ifenprodil, The risk or severity of adverse effects can be increased when Zaleplon is combined with Ifenprodil.]
[A10BX03, nateglinide, Nateglinide may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N02BA16, imidazole-2-hydroxybenzoate, Imidazole salicylate may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[J01FA15, telithromycin, The metabolism of Zaleplon can be decreased when combined with Telithromycin.]
[B01AC10, indobufen, Indobufen may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[R06AX27, desloratadine, The risk or severity of adverse effects can be increased when Zaleplon is combined with Desloratadine.]
[J05AB14, valganciclovir, The therapeutic efficacy of Zaleplon can be decreased when used in combination with Valganciclovir.]
[C05BB03, invert sugar, Zaleplon may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Zaleplon may decrease the excretion rate of Iodixanol which could result in a higher serum level.]
[V08AB05, iopromide, Zaleplon may decrease the excretion rate of Iopromide which could result in a higher serum level.]
[V08AB07, ioversol, Zaleplon may decrease the excretion rate of Ioversol which could result in a higher serum level.]
[V08AB12, ioxilan, Zaleplon may decrease the excretion rate of Ioxilan which could result in a higher serum level.]
[M01AH03, valdecoxib, Valdecoxib may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N02CC05, almotriptan, The risk or severity of adverse effects can be increased when Almotriptan is combined with Zaleplon.]
[M01AH04, parecoxib, Parecoxib may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[J02AC02, itraconazole, The metabolism of Zaleplon can be decreased when combined with Itraconazole.]
[S01AD03, acyclovir, Acyclovir may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N05BA10, ketazolam, The risk or severity of adverse effects can be increased when Zaleplon is combined with Ketazolam.]
[M01AA06, kebuzone, Kebuzone may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[L01EA01, imatinib, The metabolism of Zaleplon can be decreased when combined with Imatinib.]
[J02AC04, posaconazole, The metabolism of Zaleplon can be decreased when combined with Posaconazole.]
[N03AX09, lamotrigine, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.]
[S01GX02, levocabastine, Levocabastine may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.]
[S01BA03, cortisone, The metabolism of Zaleplon can be increased when combined with Cortisone.]
[N07BC04, lofexidine, The therapeutic efficacy of Zaleplon can be increased when used in combination with Lofexidine.]
[M01AB09, lonazolac, Lonazolac may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N05CD06, lormetazepam, The risk or severity of adverse effects can be increased when Zaleplon is combined with Lormetazepam.]
[H01AA02, cosyntropin, The risk or severity of liver damage can be increased when Tetracosactide is combined with Zaleplon.]
[M02AA31, loxoprofen, Loxoprofen may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[J01DC08, loracarbef, Loracarbef may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[C09AA03, lisinopril, Lisinopril may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[A06AD01, magnesium carbonate, Zaleplon may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.]
[A03AA04, mebeverine, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.]
[N06AX13, medifoxamine, The risk or severity of adverse effects can be increased when Zaleplon is combined with Medifoxamine.]
[H02AB15, meprednisone, The metabolism of Zaleplon can be increased when combined with Meprednisone.]
[J01DH02, meropenem, Meropenem may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[R06AD04, methdilazine, The therapeutic efficacy of Zaleplon can be decreased when used in combination with Methdilazine.]
[N04AA03, methixene, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Metixene.]
[R06AE03, cyclizine, The risk or severity of adverse effects can be increased when Zaleplon is combined with Cyclizine.]
[N05CA10, cyclobarbital, The risk or severity of adverse effects can be increased when Zaleplon is combined with Cyclobarbital.]
[C03DA04, eplerenone, Eplerenone may increase the excretion rate of Zaleplon which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AD03, metylperon, The risk or severity of adverse effects can be increased when Zaleplon is combined with Melperone.]
[C03AA07, cyclopenthiazide, Cyclopenthiazide may increase the excretion rate of Zaleplon which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF07, tenofovir disoproxil, Tenofovir disoproxil may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be decreased when combined with Zaleplon.]
[N06AX07, minaprine, The risk or severity of adverse effects can be increased when Minaprine is combined with Zaleplon.]
[S01XA18, cyclosporine, The metabolism of Cyclosporine can be decreased when combined with Zaleplon.]
[N06AG02, moclobemide, The risk or severity of adverse effects can be increased when Zaleplon is combined with Moclobemide.]
[N06BA07, modafinil, The metabolism of Zaleplon can be increased when combined with Modafinil.]
[R06AX02, cyproheptadine, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.]
[C10AA07, rosuvastatin, The metabolism of Rosuvastatin can be decreased when combined with Zaleplon.]
[M02AA02, mofebutazone, Mofebutazone may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[M01AX22, morniflumate, Morniflumate may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[C03XA02, conivaptan, The metabolism of Zaleplon can be decreased when combined with Conivaptan.]
[G04BE09, vardenafil, The metabolism of Zaleplon can be decreased when combined with Vardenafil.]
[M01AH05, etoricoxib, Etoricoxib may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[L01AX04, dacarbazine, Dacarbazine may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[G03XA01, danazol, The metabolism of Zaleplon can be decreased when combined with Danazol.]
[M03CA01, dantrolene, The risk or severity of adverse effects can be increased when Zaleplon is combined with Dantrolene.]
[J04BA02, dapsone, The metabolism of Zaleplon can be decreased when combined with Dapsone.]
[L01DB02, daunorubicin, The metabolism of Zaleplon can be increased when combined with Daunorubicin.]
[N06BX04, deanol, The risk or severity of adverse effects can be increased when Zaleplon is combined with Deanol.]
[A04AD11, nabilone, Nabilone may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.]
[M01AX01, nabumetone, Nabumetone may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N07BB05, nalmefene, Zaleplon may decrease the excretion rate of Nalmefene which could result in a higher serum level.]
[N05BA16, nordazepam, The risk or severity of adverse effects can be increased when Zaleplon is combined with Nordazepam.]
[S01GX04, nedocromil, Nedocromil may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N06AX06, nefazodone, The metabolism of Zaleplon can be decreased when combined with Nefazodone.]
[N05CM16, niaprazine, The risk or severity of adverse effects can be increased when Zaleplon is combined with Niaprazine.]
[C01DX16, nicorandil, Zaleplon may decrease the excretion rate of Nicorandil which could result in a higher serum level.]
[L02BB02, nilutamide, Nilutamide may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N03AG06, tiagabine, The risk or severity of adverse effects can be increased when Tiagabine is combined with Zaleplon.]
[G03DB04, nomegestrol, The metabolism of Nomegestrol can be increased when combined with Zaleplon.]
[C01CA23, theodrenaline, Zaleplon may increase the excretion rate of Theodrenaline which could result in a lower serum level and potentially a reduction in efficacy.]
[M03AC11, cisatracurium, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Zaleplon.]
[R05DA06, normethadone, The risk or severity of adverse effects can be increased when Zaleplon is combined with Normethadone.]
[B01AX05, fondaparinux, Fondaparinux may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N06AB10, escitalopram, The risk or severity of adverse effects can be increased when Zaleplon is combined with Escitalopram.]
[G04BD08, solifenacin, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.]
[A07EC03, olsalazine, Olsalazine may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N06AA01, desipramine, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Desipramine.]
[H01BA02, desmopressin, Desmopressin may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[V04CH02, indigo carmine, Zaleplon may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[J01DH03, ertapenem, Ertapenem may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[M01AE12, oxaprozin, Oxaprozin may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N03AF02, oxcarbazepine, The risk or severity of adverse effects can be increased when Oxcarbazepine is combined with Zaleplon.]
[S03BA01, dexamethasone, The metabolism of Zaleplon can be increased when combined with Dexamethasone.]
[N06BX07, oxiracetam, The risk or severity of adverse effects can be increased when Zaleplon is combined with Oxiracetam.]
[N04AA08, dexetimide, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.]
[G04BD04, oxybutynin, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A03AA01, oxyphencyclimine, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.]
[L04AB04, adalimumab, The metabolism of Zaleplon can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The metabolism of Zaleplon can be decreased when combined with Gefitinib.]
[N06BA02, dextroamphetamine, The therapeutic efficacy of Zaleplon can be decreased when used in combination with Amphetamine.]
[R05DA09, dextromethorphan, The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Zaleplon.]
[N03AC01, paramethadione, The risk or severity of adverse effects can be increased when Paramethadione is combined with Zaleplon.]
[N02AC01, dextromoramide, The risk or severity of adverse effects can be increased when Zaleplon is combined with Dextromoramide.]
[N06AB05, paroxetine, The risk or severity of adverse effects can be increased when Zaleplon is combined with Paroxetine.]
[B01AC04, clopidogrel, The metabolism of Zaleplon can be decreased when combined with Clopidogrel.]
[N07BC06, heroin, The risk or severity of adverse effects can be increased when Zaleplon is combined with Diamorphine.]
[C04AD01, pentifylline, Zaleplon may increase the excretion rate of Pentifylline which could result in a lower serum level and potentially a reduction in efficacy.]
[P03AC04, permethrin, Zaleplon may decrease the excretion rate of Permethrin which could result in a higher serum level.]
[N05BA01, diazepam, The risk or severity of adverse effects can be increased when Diazepam is combined with Zaleplon.]
[N03AX07, phenacemide, The risk or severity of adverse effects can be increased when Zaleplon is combined with Phenacemide.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Zaleplon is combined with Phenol.]
[N03AD02, phensuximide, The risk or severity of adverse effects can be increased when Phensuximide is combined with Zaleplon.]
[N06AA08, dibenzepin, The risk or severity of adverse effects can be increased when Zaleplon is combined with Dibenzepin.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Zaleplon is combined with Cinchocaine.]
[R05DA08, pholcodine, Zaleplon may decrease the excretion rate of Pholcodine which could result in a higher serum level.]
[S01EC02, dichlorphenamide, Diclofenamide may increase the excretion rate of Zaleplon which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC03, diclofenac, Diclofenac may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[J05AD01, foscarnet, Foscarnet may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[A03AA07, dicyclomine, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.]
[J05AF02, didanosine, Didanosine may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Zaleplon is combined with Pipamperone.]
[A03AB14, pipenzolate, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Zaleplon.]
[C03CA03, piretanide, Piretanide may increase the excretion rate of Zaleplon which could result in a lower serum level and potentially a reduction in efficacy.]
[A08AA03, diethylpropion, The risk or severity of adverse effects can be increased when Diethylpropion is combined with Zaleplon.]
[L02AA01, diethylstilbestrol, The metabolism of Diethylstilbestrol can be increased when combined with Zaleplon.]
[C08CA03, isradipine, The metabolism of Zaleplon can be decreased when combined with Isradipine.]
[D07XC04, diflucortolone, The metabolism of Zaleplon can be increased when combined with Difluocortolone.]
[A03AB11, poldine, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Poldine.]
[N02BA11, diflunisal, Diflunisal may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[C01AA05, digoxin, Zaleplon may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N02CA01, dihydroergotamine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Zaleplon.]
[N02AA03, hydromorphone, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Zaleplon.]
[L04AX04, lenalidomide, Lenalidomide may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[J05AE08, atazanavir, The metabolism of Zaleplon can be decreased when combined with Atazanavir.]
[H03BC01, potassium perchlorate, Zaleplon may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.]
[V03AB04, pralidoxime, Pralidoxime may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Zaleplon is combined with Pramocaine.]
[C08DB01, diltiazem, The metabolism of Zaleplon can be decreased when combined with Diltiazem.]
[R06AA11, dimenhydrinate, The risk or severity of adverse effects can be increased when Zaleplon is combined with Dimenhydrinate.]
[V03AB09, dimercaprol, Zaleplon may decrease the excretion rate of Dimercaprol which could result in a higher serum level.]
[M03BX03, pridinol, The risk or severity of adverse effects can be increased when Zaleplon is combined with Pridinol.]
[R06AB03, dimethindene, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.]
[M02AX03, dimethyl sulfoxide, Zaleplon may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.]
[N03AG05, progabide, The risk or severity of adverse effects can be increased when Progabide is combined with Zaleplon.]
[N06BC02, propentofylline, Zaleplon may increase the excretion rate of Propentofylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BB04, propyphenazone, Propyphenazone may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[M01AB14, proglumetacin, Proglumetacin may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Zaleplon is combined with Proparacaine.]
[R03DA03, proxyphylline, Zaleplon may increase the excretion rate of Proxyphylline which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Zaleplon is combined with Diphenhydramine.]
[A07DA01, diphenoxylate, The risk or severity of adverse effects can be increased when Zaleplon is combined with Diphenoxylate.]
[N05CD10, quazepam, The risk or severity of adverse effects can be increased when Zaleplon is combined with Quazepam.]
[N06BA11, dexmethylphenidate, The risk or severity of adverse effects can be increased when Zaleplon is combined with Dexmethylphenidate.]
[N06AA23, quinupramine, The risk or severity of adverse effects can be increased when Zaleplon is combined with Quinupramine.]
[A03FA02, cisapride, The risk or severity of adverse effects can be increased when Cisapride is combined with Zaleplon.]
[S01XA23, sirolimus, The metabolism of Sirolimus can be decreased when combined with Zaleplon.]
[N05AL04, remoxipride, The risk or severity of adverse effects can be increased when Remoxipride is combined with Zaleplon.]
[S01AX06, resorcinol, Zaleplon may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[C01BA03, disopyramide, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[P03AA04, disulfiram, The therapeutic efficacy of Zaleplon can be decreased when used in combination with Disulfiram.]
[S02AA12, rifamycin SV, The metabolism of Zaleplon can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Zaleplon can be increased when combined with Rifapentine.]
[N07XX02, riluzole, The risk or severity of adverse effects can be increased when Riluzole is combined with Zaleplon.]
[N05AX08, risperidone, The risk or severity of adverse effects can be increased when Risperidone is combined with Zaleplon.]
[R06AE09, levocetirizine, The risk or severity of adverse effects can be increased when Zaleplon is combined with Levocetirizine.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Zaleplon is combined with Ropivacaine.]
[L01EX01, sunitinib, The metabolism of Sunitinib can be decreased when combined with Zaleplon.]
[A04AD12, aprepitant, The metabolism of Zaleplon can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, Tolvaptan may increase the excretion rate of Zaleplon which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BE08, tadalafil, Tadalafil may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[S01BC05, ketorolac, Ketorolac may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[C02KX02, ambrisentan, The metabolism of Ambrisentan can be decreased when combined with Zaleplon.]
[C01EB18, ranolazine, Ranolazine may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N02BA06, salsalate, Salsalate may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[R03AC12, salmeterol, The metabolism of Zaleplon can be decreased when combined with Salmeterol.]
[H05BA01, salmon calcitonin, Salmon calcitonin may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[C01CA07, dobutamine, Dobutamine may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[A03FA03, domperidone, The metabolism of Domperidone can be decreased when combined with Zaleplon.]
[C01CA04, dopamine, Zaleplon may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[N06AA16, dothiepin, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Dosulepin.]
[N06AA12, doxepin, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[J01AA02, doxycycline, Doxycycline may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.]
[N06AB06, sertraline, The risk or severity of adverse effects can be increased when Zaleplon is combined with Sertraline.]
[N01AB08, sevoflurane, The risk or severity of adverse effects can be increased when Zaleplon is combined with Sevoflurane.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.]
[A08AA10, sibutramine, The risk or severity of adverse effects can be increased when Zaleplon is combined with Sibutramine.]
[C10AA01, simvastatin, The metabolism of Zaleplon can be decreased when combined with Simvastatin.]
[V03AG05, sodium phosphate, The therapeutic efficacy of Zaleplon can be decreased when used in combination with Sodium phosphate, monobasic.]
[A12CA02, sodium sulfate, Zaleplon may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.]
[R03DA01, dyphylline, Zaleplon may increase the excretion rate of Dyphylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AL02, sultopride, The risk or severity of adverse effects can be increased when Zaleplon is combined with Sultopride.]
[N02CC01, sumatriptan, The risk or severity of adverse effects can be increased when Sumatriptan is combined with Zaleplon.]
[V04CX07, edrophonium, Zaleplon may decrease the excretion rate of Edrophonium which could result in a higher serum level.]
[L01AX03, temozolomide, Temozolomide may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[M01AC02, tenoxicam, Tenoxicam may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[A08AB01, orlistat, Orlistat can cause a decrease in the absorption of Zaleplon resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M03BX07, tetrazepam, The risk or severity of adverse effects can be increased when Zaleplon is combined with Tetrazepam.]
[M03BX05, thiocolchicoside, The risk or severity of adverse effects can be increased when Zaleplon is combined with Thiocolchicoside.]
[N05AB05, thiopropazate, The risk or severity of adverse effects can be increased when Zaleplon is combined with Thiopropazate.]
[G04BD01, emepronium, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Emepronium.]
[N06AX14, tianeptine, The risk or severity of adverse effects can be increased when Zaleplon is combined with Tianeptine.]
[N05BA23, tofisopam, The risk or severity of adverse effects can be increased when Zaleplon is combined with Tofisopam.]
[M01AG02, tolfenamic acid, Tolfenamic acid may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N06AG03, toloxatone, The risk or severity of adverse effects can be increased when Zaleplon is combined with Toloxatone.]
[N06BA09, atomoxetine, Atomoxetine may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N03AX11, topiramate, The risk or severity of adverse effects can be increased when Topiramate is combined with Zaleplon.]
[C03CA04, torsemide, Torasemide may increase the excretion rate of Zaleplon which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD11, triazulenone, The risk or severity of adverse effects can be increased when Zaleplon is combined with Loprazolam.]
[N05CC01, chloral hydrate, The risk or severity of adverse effects can be increased when Zaleplon is combined with Chloral hydrate.]
[N05CM07, triclofos, The risk or severity of adverse effects can be increased when Zaleplon is combined with Triclofos.]
[A03AB08, tridihexethyl, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.]
[R06AA10, trimethobenzamide, The risk or severity of adverse effects can be increased when Trimethobenzamide is combined with Zaleplon.]
[N04AA12, tropatepine, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Tropatepine.]
[N01AB04, enflurane, The risk or severity of adverse effects can be increased when Enflurane is combined with Zaleplon.]
[C02CA06, urapidil, The risk or severity of adverse effects can be increased when Zaleplon is combined with Urapidil.]
[N05AL06, veralipride, The risk or severity of adverse effects can be increased when Zaleplon is combined with Veralipride.]
[S01GX10, epinastine, The risk or severity of adverse effects can be increased when Epinastine is combined with Zaleplon.]
[N06AX16, venlafaxine, The risk or severity of adverse effects can be increased when Venlafaxine is combined with Zaleplon.]
[C08CA12, mepirodipine, The metabolism of Zaleplon can be decreased when combined with Barnidipine.]
[N05CF02, zolpidem, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[M01AB04, zomepirac, Zomepirac may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N03AX15, zonisamide, The risk or severity of adverse effects can be increased when Zonisamide is combined with Zaleplon.]
[N05CF01, zopiclone, The risk or severity of adverse effects can be increased when Zaleplon is combined with Zopiclone.]
[N05AX11, zotepine, The risk or severity of adverse effects can be increased when Zaleplon is combined with Zotepine.]
[L01XA02, carboplatin, Carboplatin may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[C02AC02, guanfacine, The risk or severity of adverse effects can be increased when Zaleplon is combined with Guanfacine.]
[C01BG01, moricizine, The risk or severity of adverse effects can be increased when Moricizine is combined with Zaleplon.]
[G02AB03, ergonovine, The risk or severity of adverse effects can be increased when Zaleplon is combined with Ergometrine.]
[C04AE01, ergoloid mesylates, USP, The risk or severity of adverse effects can be increased when Zaleplon is combined with Ergoloid mesylate.]
[N02CA02, ergotamine, The metabolism of Zaleplon can be decreased when combined with Ergotamine.]
[N03AG01, valproic acid, The risk or severity of adverse effects can be increased when Valproic acid is combined with Zaleplon.]
[L03AX05, pidotimod, Zaleplon may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[S01AA17, erythromycin, The metabolism of Zaleplon can be decreased when combined with Erythromycin.]
[N05CD04, estazolam, The risk or severity of adverse effects can be increased when Zaleplon is combined with Estazolam.]
[A02BC02, pantoprazole, Pantoprazole may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[G03CA03, estradiol, The metabolism of Estradiol can be increased when combined with Zaleplon.]
[G03CA57, estrogens, conjugated (USP), Conjugated estrogens may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[J04AK02, ethambutol, Ethambutol may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[R03BA09, fluticasone furoate, The metabolism of Zaleplon can be decreased when combined with Fluticasone furoate.]
[R03BA05, fluticasone, The metabolism of Zaleplon can be decreased when combined with Fluticasone.]
[C10AA04, fluvastatin, The metabolism of Fluvastatin can be decreased when combined with Zaleplon.]
[V08CA03, gadodiamide, Gadodiamide may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N05CM08, ethchlorvynol, The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Zaleplon.]
[L02AA03, ethinyl estradiol, The metabolism of Ethinylestradiol can be increased when combined with Zaleplon.]
[C01BD05, ibutilide, Ibutilide may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N04AA05, profenamine, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Profenamine.]
[N03AD01, ethosuximide, The risk or severity of adverse effects can be increased when Ethosuximide is combined with Zaleplon.]
[N03AB01, ethotoin, The risk or severity of adverse effects can be increased when Ethotoin is combined with Zaleplon.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Zaleplon is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Zaleplon is combined with Meloxicam.]
[S01XA06, ethylmorphine, The risk or severity of adverse effects can be increased when Zaleplon is combined with Ethylmorphine.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Zaleplon is combined with Etidocaine.]
[N01AX07, etomidate, The risk or severity of adverse effects can be increased when Etomidate is combined with Zaleplon.]
[L01CB01, etoposide, The metabolism of Etoposide can be decreased when combined with Zaleplon.]
[N05AE03, sertindole, The risk or severity of adverse effects can be increased when Zaleplon is combined with Sertindole.]
[L04AD02, tacrolimus, The metabolism of Tacrolimus can be decreased when combined with Zaleplon.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Zaleplon.]
[R06AX12, terfenadine, The metabolism of Zaleplon can be decreased when combined with Terfenadine.]
[P01AX07, trimetrexate, Zaleplon may decrease the excretion rate of Trimetrexate which could result in a higher serum level.]
[N06AX12, bupropion, The risk or severity of adverse effects can be increased when Zaleplon is combined with Bupropion.]
[N06AB08, fluvoxamine, The risk or severity of adverse effects can be increased when Zaleplon is combined with Fluvoxamine.]
[L02AE02, leuprolide, Leuprolide may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[M01CB01, gold sodium thiomalate, Zaleplon may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.]
[B05AA05, dextran, Zaleplon may decrease the excretion rate of Dextran which could result in a higher serum level.]
[V03AF02, dexrazoxane, Dexrazoxane may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[A16AA01, levocarnitine, Levocarnitine may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[C08CA02, felodipine, The metabolism of Felodipine can be decreased when combined with Zaleplon.]
[N03AX26, fenfluramine, The risk or severity of adverse effects can be increased when Fenfluramine is combined with Zaleplon.]
[M01AE04, fenoprofen, Fenoprofen may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N02AB03, fentanyl, The risk or severity of adverse effects can be increased when Fentanyl is combined with Zaleplon.]
[R03CC02, albuterol, Zaleplon may decrease the excretion rate of Salbutamol which could result in a higher serum level.]
[L01BB06, clofarabine, Clofarabine may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N07AX03, cevimeline, Cevimeline may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[G04BD02, flavoxate, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.]
[N02BG04, floctafenine, Floctafenine may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[J02AC01, fluconazole, The metabolism of Zaleplon can be decreased when combined with Fluconazole.]
[J02AX01, flucytosine, Zaleplon may decrease the excretion rate of Flucytosine which could result in a higher serum level.]
[V03AB25, flumazenil, Flumazenil may decrease the sedative activities of Zaleplon.]
[N07CA03, flunarizine, The risk or severity of adverse effects can be increased when Zaleplon is combined with Flunarizine.]
[N05CD03, flunitrazepam, The risk or severity of adverse effects can be increased when Zaleplon is combined with Flunitrazepam.]
[D07AC08, fluocinonide, The metabolism of Zaleplon can be increased when combined with Fluocinonide.]
[N06AA14, melitracen, The risk or severity of adverse effects can be increased when Zaleplon is combined with Melitracen.]
[H02AB03, fluocortolone, The metabolism of Zaleplon can be increased when combined with Fluocortolone.]
[V03AZ01, ethanol, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Ethanol.]
[L01BC09, floxuridine, Floxuridine may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N06AB03, fluoxetine, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N05AF01, flupenthixol, Flupentixol may increase the sedative activities of Zaleplon.]
[N05AB02, fluphenazine, The risk or severity of adverse effects can be increased when Fluphenazine is combined with Zaleplon.]
[N05CD01, flurazepam, The risk or severity of adverse effects can be increased when Flurazepam is combined with Zaleplon.]
[S01BC04, flurbiprofen, Flurbiprofen may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N05AG01, fluspirilene, The risk or severity of adverse effects can be increased when Zaleplon is combined with Fluspirilene.]
[L02BB01, flutamide, Flutamide may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[V04CX02, folic acid, Folic acid may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[S02AA17, fosfomycin, Fosfomycin may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[S01AA07, framycetin, Framycetin may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Zaleplon.]
[M03AA01, alcuronium, The risk or severity of adverse effects can be increased when Zaleplon is combined with Alcuronium.]
[G01AX06, furazolidone, The risk or severity of adverse effects can be increased when Furazolidone is combined with Zaleplon.]
[J05AE10, darunavir, The metabolism of Zaleplon can be decreased when combined with Darunavir.]
[C03CA01, furosemide, Furosemide may increase the excretion rate of Zaleplon which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Zaleplon is combined with Eszopiclone.]
[N05AL05, amisulpride, The risk or severity of adverse effects can be increased when Zaleplon is combined with Amisulpride.]
[M03AC02, gallamine, The risk or severity of adverse effects can be increased when Zaleplon is combined with Gallamine.]
[S01AD09, ganciclovir, The therapeutic efficacy of Zaleplon can be decreased when used in combination with Ganciclovir.]
[N03AA04, barbexaclone, The risk or severity of adverse effects can be increased when Zaleplon is combined with Barbexaclone.]
[N06AX08, bifemelane, The risk or severity of adverse effects can be increased when Zaleplon is combined with Bifemelane.]
[C10AB04, gemfibrozil, Zaleplon may decrease the excretion rate of Gemfibrozil which could result in a higher serum level.]
[J01XA03, telavancin, Zaleplon may decrease the excretion rate of Telavancin which could result in a higher serum level.]
[L01EA02, dasatinib, The metabolism of Dasatinib can be decreased when combined with Zaleplon.]
[N04BC06, cabergoline, The risk or severity of adverse effects can be increased when Cabergoline is combined with Zaleplon.]
[C01CA21, cafedrine, Zaleplon may increase the excretion rate of Cafedrine which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AD03, methsuximide, The risk or severity of adverse effects can be increased when Zaleplon is combined with Methsuximide.]
[G03XA02, gestrinone, The metabolism of Gestrinone can be increased when combined with Zaleplon.]
[N01AH02, alfentanil, The risk or severity of adverse effects can be increased when Alfentanil is combined with Zaleplon.]
[L01EH01, lapatinib, The metabolism of Lapatinib can be decreased when combined with Zaleplon.]
[A10BB01, glyburide, The metabolism of Glyburide can be decreased when combined with Zaleplon.]
[A10BB07, glipizide, Zaleplon may decrease the excretion rate of Glipizide which could result in a higher serum level.]
[N05CM18, dexmedetomidine, The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Zaleplon.]
[N05CE01, glutethimide, The risk or severity of adverse effects can be increased when Zaleplon is combined with Glutethimide.]
[L01EX02, sorafenib, The metabolism of Sorafenib can be decreased when combined with Zaleplon.]
[M01CB04, aurothioglucose, Zaleplon may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Zaleplon may decrease the excretion rate of Pegaptanib which could result in a higher serum level.]
[C09AA09, fosinopril, Fosinopril may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[S01EX01, guanethidine, Zaleplon may decrease the excretion rate of Guanethidine which could result in a higher serum level.]
[L02AE03, goserelin, Goserelin may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[P01BX01, halofantrine, The therapeutic efficacy of Zaleplon can be decreased when used in combination with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of CNS depression can be increased when Haloperidol is combined with Zaleplon.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Zaleplon is combined with Halothane.]
[N05AH04, quetiapine, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.]
[N06BX13, idebenone, Zaleplon may decrease the excretion rate of Idebenone which could result in a higher serum level.]
[N02CX03, iprazochrome, The risk or severity of adverse effects can be increased when Zaleplon is combined with Iprazochrome.]
[L01CE02, irinotecan, The metabolism of Zaleplon can be decreased when combined with Irinotecan.]
[N05CA21, allobarbital, The risk or severity of adverse effects can be increased when Zaleplon is combined with Allobarbital.]
[M04AA01, allopurinol, Allopurinol may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[G03DC01, allylestrenol, Zaleplon may decrease the excretion rate of Allylestrenol which could result in a higher serum level.]
[A07EC02, mesalamine, Mesalazine may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[C01CE02, milrinone, Milrinone may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N05CA16, hexobarbital, The risk or severity of adverse effects can be increased when Zaleplon is combined with Hexobarbital.]
[J05AG01, nevirapine, The metabolism of Zaleplon can be decreased when combined with Nevirapine.]
[C08CA10, nilvadipine, The metabolism of Zaleplon can be decreased when combined with Nilvadipine.]
[M02AA26, nimesulide, Nimesulide may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[C09AA04, perindopril, Perindopril may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[C02DB02, hydralazine, Zaleplon may decrease the excretion rate of Hydralazine which could result in a higher serum level.]
[C03AA03, hydrochlorothiazide, Hydrochlorothiazide may increase the excretion rate of Zaleplon which could result in a lower serum level and potentially a reduction in efficacy.]
[R05DA03, hydrocodone, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[S02BA01, hydrocortisone, The metabolism of Zaleplon can be decreased when combined with Hydrocortisone.]
[D07AB02, hydrocortisone butyrate, The metabolism of Hydrocortisone butyrate can be decreased when combined with Zaleplon.]
[C03AA02, hydroflumethiazide, Hydroflumethiazide may increase the excretion rate of Zaleplon which could result in a lower serum level and potentially a reduction in efficacy.]
[B05XA17, potassium acetate, Zaleplon may decrease the excretion rate of Potassium acetate which could result in a higher serum level.]
[A12BA02, potassium citrate, Potassium citrate may increase the excretion rate of Zaleplon which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB33, hydroxocobalamin, Hydroxocobalamin may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[G04BD06, propiverine, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Propiverine.]
[P01BA02, hydroxychloroquine, The therapeutic efficacy of Zaleplon can be decreased when used in combination with Hydroxychloroquine.]
[N05AX07, prothipendyl, The risk or severity of adverse effects can be increased when Zaleplon is combined with Prothipendyl.]
[B05AA07, hetastarch, Zaleplon may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[N05BB01, hydroxyzine, Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.]
[R02AX02, ibuprofen, Ibuprofen may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[B05XA08, sodium acetate, Zaleplon may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[L01AA06, ifosfamide, The metabolism of Ifosfamide can be decreased when combined with Zaleplon.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Sufentanil is combined with Zaleplon.]
[N06AA02, imipramine, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Imipramine.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be decreased when combined with Zaleplon.]
[R01AD07, tixocortol, Zaleplon may decrease the excretion rate of Tixocortol which could result in a higher serum level.]
[M03BX02, tizanidine, The risk or severity of adverse effects can be increased when Tizanidine is combined with Zaleplon.]
[L01CE01, topotecan, Zaleplon may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[C03BA11, indapamide, Indapamide may increase the excretion rate of Zaleplon which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC01, indomethacin, Indomethacin may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[A11HA07, inositol, Zaleplon may decrease the excretion rate of Inositol which could result in a higher serum level.]
[N06AX17, milnacipran, The risk or severity of adverse effects can be increased when Zaleplon is combined with Milnacipran.]
[A03AA30, piperidolate, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.]
[S01XA28, varenicline, Zaleplon may decrease the excretion rate of Varenicline which could result in a higher serum level.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Zaleplon is combined with Articaine.]
[A10BH01, sitagliptin, Zaleplon may decrease the excretion rate of Sitagliptin which could result in a higher serum level.]
[V08AB02, iohexol, The therapeutic efficacy of Zaleplon can be decreased when used in combination with Iohexol.]
[N05BA12, alprazolam, The risk or severity of adverse effects can be increased when Alprazolam is combined with Zaleplon.]
[N05CH02, ramelteon, The risk or severity of adverse effects can be increased when Zaleplon is combined with Ramelteon.]
[R06AE01, buclizine, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Buclizine.]
[C10AA06, cerivastatin, The metabolism of Zaleplon can be decreased when combined with Cerivastatin.]
[C07AA01, alprenolol, The risk or severity of adverse effects can be increased when Alprenolol is combined with Zaleplon.]
[C03BA02, quinethazone, Quinethazone may increase the excretion rate of Zaleplon which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB01, ipecac, Zaleplon may decrease the excretion rate of Ipecac which could result in a higher serum level.]
[N06AA13, iprindole, The risk or severity of adverse effects can be increased when Zaleplon is combined with Iprindole.]
[N06AF05, iproniazid, The risk or severity of adverse effects can be increased when Zaleplon is combined with Iproniazid.]
[N05AA07, chlorproethazine, The risk or severity of adverse effects can be increased when Zaleplon is combined with Chlorproethazine.]
[N06AF01, isocarboxazid, The risk or severity of adverse effects can be increased when Zaleplon is combined with Isocarboxazid.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Isoflurane is combined with Zaleplon.]
[N04BX02, entacapone, The risk or severity of adverse effects can be increased when Entacapone is combined with Zaleplon.]
[J04AC01, isoniazid, The metabolism of Zaleplon can be decreased when combined with Isoniazid.]
[J05AX05, inosine pranobex, Zaleplon may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[C01DA14, isosorbide mononitrate, Zaleplon may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.]
[D10BA01, isotretinoin, Zaleplon may decrease the excretion rate of Isotretinoin which could result in a higher serum level.]
[N06AX18, reboxetine, The risk or severity of adverse effects can be increased when Reboxetine is combined with Zaleplon.]
[S01AA24, kanamycin, Zaleplon may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[L04AC07, tocilizumab, The metabolism of Zaleplon can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The risk or severity of adverse effects can be increased when Zaleplon is combined with Ketamine.]
[C02KD01, ketanserin, The risk or severity of adverse effects can be increased when Zaleplon is combined with Ketanserin.]
[B01AC22, prasugrel, Zaleplon may decrease the excretion rate of Prasugrel which could result in a higher serum level.]
[H02CA04, levoketoconazole, The metabolism of Zaleplon can be decreased when combined with Levoketoconazole.]
[J02AB02, ketoconazole, The metabolism of Zaleplon can be decreased when combined with Ketoconazole.]
[N05AH03, olanzapine, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.]
[M02AA10, ketoprofen, Ketoprofen may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[L04AA24, abatacept, The metabolism of Zaleplon can be increased when combined with Abatacept.]
[N04BC09, rotigotine, Zaleplon may increase the sedative activities of Rotigotine.]
[D10AX03, azelaic acid, Azelaic acid may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[J01MB02, nalidixic acid, The therapeutic efficacy of Zaleplon can be decreased when used in combination with Nalidixic acid.]
[M01AE11, tiaprofenic acid, Tiaprofenic acid may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[D11AX02, gamma-linolenic acid, The therapeutic efficacy of Zaleplon can be decreased when used in combination with Gamolenic acid.]
[C07AG01, labetalol, Labetalol may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N04BB01, amantadine, Amantadine may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[A06AX03, lubiprostone, Zaleplon may decrease the excretion rate of Lubiprostone which could result in a higher serum level.]
[N03AX18, lacosamide, The risk or severity of adverse effects can be increased when Zaleplon is combined with Lacosamide.]
[C03CC01, ethacrynic acid, Etacrynic acid may increase the excretion rate of Zaleplon which could result in a lower serum level and potentially a reduction in efficacy.]
[G03AD01, levonorgestrel, The metabolism of Levonorgestrel can be increased when combined with Zaleplon.]
[N04BA01, levodopa, The risk or severity of adverse effects can be increased when Zaleplon is combined with Levodopa.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Zaleplon is combined with Lidocaine.]
[S01AA21, amikacin, Zaleplon may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[N06BA13, armodafinil, The metabolism of Zaleplon can be increased when combined with Armodafinil.]
[C03DB01, amiloride, Amiloride may increase the excretion rate of Zaleplon which could result in a lower serum level and potentially a reduction in efficacy.]
[N02CA07, lisuride, The risk or severity of adverse effects can be increased when Lisuride is combined with Zaleplon.]
[N06AA07, lofepramine, The risk or severity of adverse effects can be increased when Zaleplon is combined with Lofepramine.]
[N05BA06, lorazepam, The risk or severity of adverse effects can be increased when Lorazepam is combined with Zaleplon.]
[C10AA02, lovastatin, The metabolism of Zaleplon can be decreased when combined with Lovastatin.]
[N05AH01, loxapine, The risk or severity of adverse effects can be increased when Loxapine is combined with Zaleplon.]
[G03DC03, lynestrenol, The metabolism of Lynestrenol can be increased when combined with Zaleplon.]
[L01EG01, temsirolimus, The metabolism of Temsirolimus can be decreased when combined with Zaleplon.]
[B05XA11, magnesium chloride, Zaleplon may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.]
[G04BX01, magnesium hydroxide, Zaleplon may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Zaleplon can be increased when used in combination with Magnesium sulfate.]
[L01BA05, pralatrexate, Zaleplon may decrease the excretion rate of Pralatrexate which could result in a higher serum level.]
[L01EA03, nilotinib, The metabolism of Zaleplon can be decreased when combined with Nilotinib.]
[V04CX04, mannitol, Mannitol may increase the excretion rate of Zaleplon which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA21, maprotiline, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.]
[A08AA05, mazindol, The risk or severity of adverse effects can be increased when Mazindol is combined with Zaleplon.]
[C02BB01, mecamylamine, Mecamylamine may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[R06AE05, meclizine, The risk or severity of adverse effects can be increased when Meclizine is combined with Zaleplon.]
[M02AA18, meclofenamic acid, Meclofenamic acid may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N05BA03, medazepam, The risk or severity of adverse effects can be increased when Zaleplon is combined with Medazepam.]
[P01BC02, mefloquine, The therapeutic efficacy of Zaleplon can be decreased when used in combination with Mefloquine.]
[C03BA05, mefruside, Mefruside may increase the excretion rate of Zaleplon which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CH01, melatonin, The risk or severity of adverse effects can be increased when Zaleplon is combined with Melatonin.]
[N06DX01, memantine, Zaleplon may decrease the excretion rate of Memantine which could result in a higher serum level.]
[N02AB02, meperidine, The risk or severity of adverse effects can be increased when Meperidine is combined with Zaleplon.]
[N03AB04, mephenytoin, The risk or severity of adverse effects can be increased when Mephenytoin is combined with Zaleplon.]
[N03AA01, mephobarbital, The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Zaleplon.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Zaleplon is combined with Mepivacaine.]
[N05BC01, meprobamate, The risk or severity of adverse effects can be increased when Meprobamate is combined with Zaleplon.]
[N02AX05, meptazinol, The risk or severity of adverse effects can be increased when Zaleplon is combined with Meptazinol.]
[G04BX16, tiopronin, Zaleplon may decrease the excretion rate of Tiopronin which could result in a higher serum level.]
[C03BC01, mersalyl, Mersalyl may increase the excretion rate of Zaleplon which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AC03, mesoridazine, The risk or severity of adverse effects can be increased when Mesoridazine is combined with Zaleplon.]
[N05AX13, paliperidone, The risk or severity of adverse effects can be increased when Zaleplon is combined with Paliperidone.]
[A10BA02, metformin, Metformin may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[A04AA04, dolasetron, The risk or severity of adverse effects can be increased when Dolasetron is combined with Zaleplon.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Zaleplon.]
[N06BA03, methamphetamine, The risk or severity of adverse effects can be increased when Zaleplon is combined with Metamfetamine.]
[A03AB07, methantheline, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Methantheline.]
[R06AC05, methapyrilene, The risk or severity of adverse effects can be increased when Zaleplon is combined with Methapyrilene.]
[N05CM01, methaqualone, The risk or severity of adverse effects can be increased when Zaleplon is combined with Methaqualone.]
[J05AF05, lamivudine, Lamivudine may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N03AA30, metharbital, The risk or severity of adverse effects can be increased when Metharbital is combined with Zaleplon.]
[S01EC05, methazolamide, Methazolamide may increase the excretion rate of Zaleplon which could result in a lower serum level and potentially a reduction in efficacy.]
[G02CB05, metergoline, The risk or severity of adverse effects can be increased when Zaleplon is combined with Metergoline.]
[H03BB02, methimazole, The metabolism of Zaleplon can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, Zaleplon may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[M03BA03, methocarbamol, The risk or severity of adverse effects can be increased when Methocarbamol is combined with Zaleplon.]
[N05CA15, methohexital, The risk or severity of adverse effects can be increased when Methohexital is combined with Zaleplon.]
[A11HA02, pyridoxine, Pyridoxine may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N02BG08, ziconotide, The risk or severity of CNS depression can be increased when Zaleplon is combined with Ziconotide.]
[L04AX03, methotrexate, Methotrexate may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N05AA02, methotrimeprazine, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[D05BA02, methoxsalen, Methoxsalen may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N02BG09, methoxyflurane, The risk or severity of adverse effects can be increased when Zaleplon is combined with Methoxyflurane.]
[C03AA08, methyclothiazide, Methyclothiazide may increase the excretion rate of Zaleplon which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AB01, methyldopa, Zaleplon may decrease the excretion rate of Methyldopa which could result in a higher serum level.]
[V04CG05, methylene blue, The risk or severity of adverse effects can be increased when Zaleplon is combined with Methylene blue.]
[R03DA05, aminophylline, Zaleplon may increase the excretion rate of Aminophylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N06BA04, methylphenidate, The therapeutic efficacy of Zaleplon can be decreased when used in combination with Methylphenidate.]
[N03AF03, rufinamide, The risk or severity of adverse effects can be increased when Rufinamide is combined with Zaleplon.]
[G03EK01, methyltestosterone, Zaleplon may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.]
[N05CE02, methyprylon, The risk or severity of adverse effects can be increased when Zaleplon is combined with Methyprylon.]
[N02CA04, methysergide, The risk or severity of adverse effects can be increased when Methysergide is combined with Zaleplon.]
[A03FA01, metoclopramide, The risk or severity of sedation can be increased when Metoclopramide is combined with Zaleplon.]
[C03BA08, metolazone, Metolazone may increase the excretion rate of Zaleplon which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB02, metoprolol, Metoprolol may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[P01AB01, metronidazole, The therapeutic efficacy of Zaleplon can be decreased when used in combination with Metronidazole.]
[V04CD01, metyrapone, Zaleplon may decrease the excretion rate of Metyrapone which could result in a higher serum level.]
[N06AX03, mianserin, The therapeutic efficacy of Zaleplon can be decreased when used in combination with Mianserin.]
[S02AA13, miconazole, The metabolism of Zaleplon can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, Aminophenazone may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N05CD08, midazolam, The risk or severity of adverse effects can be increased when Midazolam is combined with Zaleplon.]
[G03XB01, mifepristone, The metabolism of Mifepristone can be increased when combined with Zaleplon.]
[J05AH01, zanamivir, Zanamivir may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.]
[L01XX23, mitotane, The metabolism of Zaleplon can be increased when combined with Mitotane.]
[N05AE02, molindone, The risk or severity of adverse effects can be increased when Zaleplon is combined with Molindone.]
[L03AC01, aldesleukin, Aldesleukin may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[C01BD01, amiodarone, The metabolism of Zaleplon can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Morphine is combined with Zaleplon.]
[A04AA05, palonosetron, The risk or severity of adverse effects can be increased when Palonosetron is combined with Zaleplon.]
[J01DD06, moxalactam, Latamoxef may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[L04AB05, certolizumab pegol, The metabolism of Zaleplon can be increased when combined with Certolizumab pegol.]
[G04BA01, ammonium chloride, Zaleplon may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.]
[L04AA06, mycophenolic acid, Zaleplon may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.]
[M03AC03, vecuronium, The risk or severity of adverse effects can be increased when Zaleplon is combined with Vecuronium.]
[N05CA02, amobarbital, The risk or severity of adverse effects can be increased when Zaleplon is combined with Amobarbital.]
[R03BB01, ipratropium bromide, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AA17, amoxapine, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.]
[N03AB05, fosphenytoin, The metabolism of Zaleplon can be increased when combined with Fosphenytoin.]
[C07AA12, nadolol, Zaleplon may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[J01CA04, amoxicillin, Zaleplon may decrease the excretion rate of Amoxicillin which could result in a higher serum level.]
[N04BC04, ropinirole, Zaleplon may increase the sedative activities of Ropinirole.]
[C04AX21, nafronyl, The risk or severity of adverse effects can be increased when Zaleplon is combined with Naftidrofuryl.]
[N02AF02, nalbuphine, The risk or severity of adverse effects can be increased when Nalbuphine is combined with Zaleplon.]
[V03AB15, naloxone, The metabolism of Zaleplon can be decreased when combined with Naloxone.]
[L04AC03, anakinra, The metabolism of Zaleplon can be increased when combined with Anakinra.]
[S01GA01, naphazoline, The risk or severity of CNS depression can be increased when Naphazoline is combined with Zaleplon.]
[N06BA01, amphetamine, The therapeutic efficacy of Zaleplon can be decreased when used in combination with Amphetamine.]
[M02AA12, naproxen, Naproxen may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[A10BG01, troglitazone, The metabolism of Zaleplon can be decreased when combined with Troglitazone.]
[N06AX21, duloxetine, The risk or severity of adverse effects can be increased when Zaleplon is combined with Duloxetine.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Tolcapone is combined with Zaleplon.]
[L01CD02, docetaxel, The metabolism of Docetaxel can be decreased when combined with Zaleplon.]
[S03AA01, neomycin, Zaleplon may decrease the excretion rate of Neomycin which could result in a higher serum level.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Remifentanil is combined with Zaleplon.]
[B01AC17, tirofiban, Tirofiban may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N05AX14, iloperidone, The risk or severity of adverse effects can be increased when Zaleplon is combined with Iloperidone.]
[J02AA01, amphotericin B, The therapeutic efficacy of Zaleplon can be decreased when used in combination with Amphotericin B.]
[S01AA19, ampicillin, Ampicillin may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[L03AX16, plerixafor, Zaleplon may decrease the excretion rate of Plerixafor which could result in a higher serum level.]
[S01AA23, netilmicin, Zaleplon may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, The risk or severity of adverse effects can be increased when Zaleplon is combined with Desvenlafaxine.]
[J05AB11, valacyclovir, Valaciclovir may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[C01CE01, inamrinone, Zaleplon may decrease the excretion rate of Amrinone which could result in a higher serum level.]
[N06AF02, nialamide, The risk or severity of adverse effects can be increased when Zaleplon is combined with Nialamide.]
[C08CA04, nicardipine, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Nicardipine.]
[C08CA05, nifedipine, Zaleplon may decrease the excretion rate of Nifedipine which could result in a higher serum level.]
[M02AA17, niflumic acid, Niflumic acid may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[C08CA07, nisoldipine, Nisoldipine may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N05CD02, nitrazepam, The risk or severity of adverse effects can be increased when Zaleplon is combined with Nitrazepam.]
[C08CA08, nitrendipine, The metabolism of Nitrendipine can be decreased when combined with Zaleplon.]
[R07AX01, nitric oxide, Nitric Oxide may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[J01XE01, nitrofurantoin, Nitrofurantoin may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N07XX04, sodium oxybate, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.]
[C01DA05, pentaerythritol tetranitrate, Zaleplon may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.]
[N04BC05, pramipexole, Zaleplon may increase the sedative activities of Pramipexole.]
[C02DD01, nitroprusside, Nitroprusside may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N01AX13, nitrous oxide, The risk or severity of adverse effects can be increased when Zaleplon is combined with Nitrous oxide.]
[N06AX04, nomifensine, The risk or severity of adverse effects can be increased when Zaleplon is combined with Nomifensine.]
[G03DC02, norethindrone, The metabolism of Norethisterone can be increased when combined with Zaleplon.]
[G03AC07, norgestrienone, The metabolism of Norgestrienone can be increased when combined with Zaleplon.]
[N06AA10, nortriptyline, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.]
[L04AC04, rilonacept, The metabolism of Zaleplon can be increased when combined with Rilonacept.]
[N06AA05, opipramol, The risk or severity of adverse effects can be increased when Zaleplon is combined with Opipramol.]
[N02AA02, opium, The risk or severity of adverse effects can be increased when Zaleplon is combined with Opium.]
[G04CA02, tamsulosin, Tamsulosin may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[J01CF04, oxacillin, Oxacillin may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N05BA04, oxazepam, The risk or severity of adverse effects can be increased when Oxazepam is combined with Zaleplon.]
[C07AA02, oxprenolol, The risk or severity of adverse effects can be increased when Zaleplon is combined with Oxprenolol.]
[N02AA05, oxycodone, The risk or severity of adverse effects can be increased when Oxycodone is combined with Zaleplon.]
[N02AA11, oxymorphone, The risk or severity of adverse effects can be increased when Zaleplon is combined with Oxymorphone.]
[N05AE01, oxypertine, The risk or severity of adverse effects can be increased when Zaleplon is combined with Oxypertine.]
[S01BC02, oxyphenbutazone, Oxyphenbutazone may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[A03AB03, oxyphenonium, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.]
[N05AH05, asenapine, The risk or severity of adverse effects can be increased when Zaleplon is combined with Asenapine.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.]
[M03AC01, pancuronium, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Pancuronium.]
[J04AB30, capreomycin, Zaleplon may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[G03DB06, chlormadinone, The metabolism of Chlormadinone can be increased when combined with Zaleplon.]
[N05CC05, paraldehyde, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.]
[H02AB05, paramethasone, The metabolism of Zaleplon can be increased when combined with Paramethasone.]
[C02KC01, pargyline, The risk or severity of adverse effects can be increased when Zaleplon is combined with Pargyline.]
[A07AA06, paromomycin, Paromomycin may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[G04BD11, fesoterodine, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.]
[C07AA23, penbutolol, The risk or severity of adverse effects can be increased when Zaleplon is combined with Penbutolol.]
[N05AG03, penfluridol, The risk or severity of adverse effects can be increased when Zaleplon is combined with Penfluridol.]
[J01CE09, penicillin G procaine, Zaleplon may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.]
[N02AD01, pentazocine, The risk or severity of adverse effects can be increased when Pentazocine is combined with Zaleplon.]
[N05CA01, pentobarbital, The metabolism of Zaleplon can be increased when combined with Pentobarbital.]
[L01XX08, pentostatin, Zaleplon may decrease the excretion rate of Pentostatin which could result in a higher serum level.]
[C04AD03, pentoxifylline, Zaleplon may increase the excretion rate of Pentoxifylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AB10, perazine, The risk or severity of adverse effects can be increased when Zaleplon is combined with Perazine.]
[N04BC02, pergolide, The risk or severity of adverse effects can be increased when Zaleplon is combined with Pergolide.]
[N05AB03, perphenazine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Zaleplon.]
[N02AD02, phenazocine, The risk or severity of adverse effects can be increased when Zaleplon is combined with Phenazocine.]
[G04BX06, phenazopyridine, Phenazopyridine may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N06AF03, phenelzine, The risk or severity of adverse effects can be increased when Phenelzine is combined with Zaleplon.]
[N03AA02, phenobarbital, The metabolism of Zaleplon can be increased when combined with Phenobarbital.]
[N01AH04, phenoperidine, The risk or severity of adverse effects can be increased when Zaleplon is combined with Phenoperidine.]
[V03AB36, phentolamine, Phentolamine may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[M02AA01, phenylbutazone, Phenylbutazone may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[R01BA01, phenylpropanolamine, The therapeutic efficacy of Zaleplon can be decreased when used in combination with Phenylpropanolamine.]
[N03AB02, phenytoin, The metabolism of Zaleplon can be increased when combined with Phenytoin.]
[L04AB06, golimumab, The metabolism of Zaleplon can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, Zaleplon may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[B02BA01, vitamin K1, Zaleplon may decrease the excretion rate of Phylloquinone which could result in a higher serum level.]
[J05AB12, cidofovir, Cidofovir may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[C08CX01, mibefradil, The metabolism of Zaleplon can be decreased when combined with Mibefradil.]
[N05AG02, pimozide, The metabolism of Pimozide can be decreased when combined with Zaleplon.]
[C07AA03, pindolol, The risk or severity of adverse effects can be increased when Pindolol is combined with Zaleplon.]
[C10AA05, atorvastatin, The metabolism of Atorvastatin can be decreased when combined with Zaleplon.]
[J01CA12, piperacillin, Piperacillin may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[J05AE01, saquinavir, The metabolism of Zaleplon can be decreased when combined with Saquinavir.]
[N05AC04, pipothiazine, The risk or severity of adverse effects can be increased when Zaleplon is combined with Pipotiazine.]
[N06BX03, piracetam, Zaleplon may decrease the excretion rate of Piracetam which could result in a higher serum level.]
[A02BX03, pirenzepine, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.]
[N02AC03, pirinitramide, The risk or severity of adverse effects can be increased when Zaleplon is combined with Piritramide.]
[S01BC06, piroxicam, Piroxicam may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[J01DD16, cefditoren, Cefditoren may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N02CX01, pizotyline, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.]
[J05AG02, delavirdine, The metabolism of Zaleplon can be decreased when combined with Delavirdine.]
[N05CA22, proxibarbal, The risk or severity of adverse effects can be increased when Zaleplon is combined with Proxibarbal.]
[A10BG02, rosiglitazone, Rosiglitazone may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[A03AE01, alosetron, The risk or severity of adverse effects can be increased when Zaleplon is combined with Alosetron.]
[L04AC08, canakinumab, The metabolism of Zaleplon can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, Polythiazide may increase the excretion rate of Zaleplon which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE03, ritonavir, The serum concentration of Zaleplon can be increased when it is combined with Ritonavir.]
[A10BH03, saxagliptin, Zaleplon may decrease the excretion rate of Saxagliptin which could result in a higher serum level.]
[B05XA01, potassium chloride, Potassium chloride may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N05BA11, prazepam, The risk or severity of adverse effects can be increased when Zaleplon is combined with Prazepam.]
[P02BA01, praziquantel, The metabolism of Praziquantel can be decreased when combined with Zaleplon.]
[H02AB07, prednisone, Prednisone may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Zaleplon is combined with Prilocaine.]
[P01BA03, primaquine, The metabolism of Zaleplon can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Zaleplon can be increased when combined with Primidone.]
[M04AB01, probenecid, Zaleplon may decrease the excretion rate of Probenecid which could result in a higher serum level.]
[C01BA02, procainamide, Zaleplon may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Zaleplon is combined with Procaine.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Zaleplon is combined with Procarbazine.]
[C10AB05, fenofibrate, Zaleplon may decrease the excretion rate of Fenofibrate which could result in a higher serum level.]
[N05AB04, prochlorperazine, The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Zaleplon.]
[N04AA04, procyclidine, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Procyclidine.]
[G03DA04, progesterone, The metabolism of Progesterone can be increased when combined with Zaleplon.]
[N05AA03, promazine, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Promazine.]
[R06AD02, promethazine, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Promethazine.]
[N01AX04, propanidid, The risk or severity of adverse effects can be increased when Zaleplon is combined with Propanidid.]
[A03AB05, propantheline, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Propantheline.]
[N05AC01, periciazine, The risk or severity of adverse effects can be increased when Zaleplon is combined with Periciazine.]
[N05CM06, propiomazine, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Propiomazine.]
[L01XH02, romidepsin, The metabolism of Romidepsin can be decreased when combined with Zaleplon.]
[N01AX10, propofol, The risk or severity of adverse effects can be increased when Propofol is combined with Zaleplon.]
[N02AC04, propoxyphene, The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Zaleplon.]
[C07AA05, propranolol, Propranolol may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N02CC04, rizatriptan, The risk or severity of adverse effects can be increased when Rizatriptan is combined with Zaleplon.]
[B01AC09, epoprostenol, Zaleplon may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[N06AA11, protriptyline, The risk or severity of adverse effects can be increased when Protriptyline is combined with Zaleplon.]
[N05AX12, aripiprazole, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.]
[N07XX07, dalfampridine, Zaleplon may decrease the excretion rate of Dalfampridine which could result in a higher serum level.]
[A03AB15, diphemanil, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.]
[A03AB09, isopropamide, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.]
[S01FA03, methscopolamine, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.]
[N05CA07, talbutal, The risk or severity of adverse effects can be increased when Talbutal is combined with Zaleplon.]
[N05CA09, vinbarbital, The risk or severity of adverse effects can be increased when Zaleplon is combined with Vinbarbital.]
[N05BB02, captodiamine, The risk or severity of adverse effects can be increased when Zaleplon is combined with Captodiame.]
[M03BA04, styramate, The risk or severity of adverse effects can be increased when Zaleplon is combined with Styramate.]
[P02CC01, pyrantel, The risk or severity of adverse effects can be increased when Zaleplon is combined with Pyrantel.]
[J04AK01, pyrazinamide, Pyrazinamide may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[R06AC01, pyrilamine, The risk or severity of adverse effects can be increased when Zaleplon is combined with Mepyramine.]
[P01AX05, quinacrine, The metabolism of Quinacrine can be decreased when combined with Zaleplon.]
[C01BA01, quinidine, The metabolism of Quinidine can be decreased when combined with Zaleplon.]
[P01BC01, quinine, The risk or severity of adverse effects can be increased when Quinine is combined with Zaleplon.]
[A02BA02, ranitidine, Ranitidine may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Reserpine is combined with Zaleplon.]
[J05AP01, ribavirin, Ribavirin may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[J04AB02, rifampin, The metabolism of Zaleplon can be increased when combined with Rifampicin.]
[N06AX01, 5-hydroxytryptophan, The risk or severity of adverse effects can be increased when Zaleplon is combined with Oxitriptan.]
[N02BA05, salicylamide, Salicylamide may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[A07EC01, sulfasalazine, Sulfasalazine may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[S01BC08, salicylic acid, Salicylic acid may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[S01FA02, scopolamine, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CA06, secobarbital, The risk or severity of adverse effects can be increased when Secobarbital is combined with Zaleplon.]
[N04BD01, selegiline, The risk or severity of adverse effects can be increased when Zaleplon is combined with Selegiline.]
[J01GB08, sisomicin, Zaleplon may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Zaleplon may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[V04CC01, sorbitol, Zaleplon may decrease the excretion rate of Sorbitol which could result in a higher serum level.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be decreased when combined with Zaleplon.]
[C03DA01, spironolactone, Spironolactone may increase the excretion rate of Zaleplon which could result in a lower serum level and potentially a reduction in efficacy.]
